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SUMMARY
Neurofibromatosis type 1 (NF1) is a common neurodevelopmental disorder caused by a spectrum of distinct germline NF1 gene muta-
tions, traditionally viewed as equivalent loss-of-function alleles. To specifically address the issue of mutational equivalency in a disease
with considerable clinical heterogeneity, we engineered seven isogenic human induced pluripotent stem cell lines, each with a different
NF1 patientNF1mutation, to identify potential differential effects of NF1mutations on human central nervous system cells and tissues.
Although all mutations increased proliferation and RAS activity in 2D neural progenitor cells (NPCs) and astrocytes, we observed striking
differences between NF1 mutations on 2D NPC dopamine levels, and 3D NPC proliferation, apoptosis, and neuronal differentiation in
developing cerebral organoids. Together, these findings demonstrate differential effects of NF1 gene mutations at the cellular and tissue
levels, suggesting that the germline NF1 gene mutation is one factor that underlies clinical variability.
INTRODUCTION
Neurofibromatosis 1 (NF1; OMIM 162200) is a neuroge-
netic condition characterized by remarkable phenotypic
variability, where affected children develop a wide variety
of central nervous system (CNS) pathologies, ranging
frombrain tumors andmotor delays to learning difficulties,
attention deficits, and autism (Fisher et al., 2018; Hyman
et al., 2006; Jett and Friedman, 2010; Korf, 2013; Morris
and Gutmann, 2018). One of many potential factors un-
derlying this clinical variability could be the specific NF1
germline mutation, a notion suggested by population-
based studies (Anastasaki et al., 2017; Bolcekova et al.,
2013; Kehrer-Sawatzki et al., 2017; Koczkowska et al.,
2018; Pinna et al., 2015; Rojnueangnit et al., 2015; Sharif
et al., 2011; Trevisson et al., 2019; Upadhyaya et al.,
2007). For example, patients harboring the c.2970–
2971_delAAT, c.5425C > T, and c.3112A > G NF1 germline
mutations lack dermal and plexiform neurofibromas, the
signature peripheral nervous system tumors in NF1 (Pinna
et al., 2015; Trevisson et al., 2019; Upadhyaya et al., 2007).
Although these studies raise the possibility that not all
NF1 gene mutations are functionally equivalent, they do
not establish differential effects of NF1 patient germline
mutations at the cellular or tissue levels, a critical step
in interpreting the significance of reported genotype-
phenotype associations. To specifically evaluate differen-
tial NF1 mutation effects on human CNS cells and tis-
sues, while controlling for important confounding
factors (e.g., sex, genomic differences), we generated an
isogenic series of human induced pluripotent stem cells
(hiPSCs) harboring seven representative NF1-patient
NF1 mutations.
RESULTS AND DISCUSSION
Generation of Isogenic NF1-Mutant hiPSCs
The seven NF1 pathogenic mutations, derived from pa-
tients in our clinic population at Washington Univer-
sity/St. Louis Children’s Hospital, represent the spectrum
of mutations typically seen in individuals with NF1. In
this regard, the selected mutations were interspersed
throughout the NF1 protein (neurofibromin) coding
sequence, were both proximal and distal to the well-char-
acterized RAS GTPase-activating protein (RAS-GAP)
domain (GRD), and included four nonsense (c.1149C >
A, c.2041C > T, c.6513T > A, c.6619C > T), one splice
site (c.1185+1G > A), one missense (c.5425C > T), and
one frameshift (c.3431-32_dupGT) mutation (Figures
1A, S1, and S2). All of the engineered isogenic hiPSCs
harbored only a single NF1 mutation (‘‘NF1-mutant’’), re-
tained expression of the remaining wild-type NF1 allele
as confirmed by DNA and RNA sequencing (Figure S1),
and expressed similar levels of NF1 mRNA (Figure 1B).
For all hiPSC lines with two clones, identical results
were obtained using numerous independently generated
biological replicates, as well as with three NF1 patient-
derived hiPSC lines generated from somatic cells (fibro-
blasts; Figure S3, Table S1).
Stem Cell Reports j Vol. 14 j 541–550 j April 14, 2020 j ª 2020 The Author(s). 541
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
ARAS GAP 
domain
NF1 
gene
c.1149C>A
p.Cys383X
c.2041C>T
p.Arg681X
c.3431-32_dupGT
p.Thr1145Val_FS
c.5425C>T
p.Arg1809Cys
c.6513T>A
p.Tyr2171X
c.6619C>T
p.Gln2207X
c.1185+1G>A
skip exon 10
0
1
2
3
D
11
85
+1
G>
A
11
49
C>
A
20
41
C>
T
34
31
-32
_d
up
GT
54
25
C>
T
65
13
T>
A
66
19
C>
T
CT
L
R
el
at
iv
e 
R
A
S
-G
TP
Vehicle
10μg/mL FGF
E 
0
1
2
3
11
85
+1
G>
A
11
49
C>
A
20
41
C>
T
34
31
-32
_d
up
GT
54
25
C>
T
65
13
T>
A
66
19
C>
T
CT
L
R
el
at
iv
e 
R
A
S
-G
TP
Vehicle
10μg/mL BDNF
H
16
D
IV
Em
br
yo
id
 
bo
di
es
56
D
IV
CTL 1149C>A 1185+1G>A 3431-32_dupGT 5425C>T 6619C>T
G
11
85
+1
G>
A
11
49
C>
A
20
41
C>
T
34
31
-32
_d
up
GT
54
25
C>
T
65
13
T>
A
66
19
C>
T
CT
L
C
el
l N
um
be
r (
x1
05
)
0
10
20
30
Clone 1
Clone 2
0
2
3
4
5
1
11
85
+1
G>
A
11
49
C>
A
20
41
C>
T
34
31
-32
_d
up
GT
54
25
C>
T
65
13
T>
A
66
19
C>
T
CT
L
R
el
at
iv
e 
O
D
40
5
B
rd
U
 L
ab
el
in
g
F Clone 1
Clone 2
B
0.0
0.5
1.0
1.5
Clone 1
Clone 2
11
85
+1
G>
A
11
49
C>
A
20
41
C>
T
34
31
-32
_d
up
GT
54
25
C>
T
65
13
T>
A
66
19
C>
T
CT
L
N
F1
 (R
.E
.)
0
1
2
11
85
+1
G>
A
11
49
C>
A
20
41
C>
T
34
31
-32
_d
up
GT
54
25
C>
T
65
13
T>
A
66
19
C>
T
CT
L
R
el
at
iv
e 
R
A
S
-G
TP
3
Clone 1
Clone 2
C
I
CT
L
11
49
C>
A
11
85
+1
G>
A
34
31
-32
_d
up
GT
54
25
C>
T
66
19
C>
T
0
1
2
3
4
5
R
el
at
iv
e
R
A
S
-G
TP
Clone 1
Clone 2
J
0
100
200
300
S
O
X
2+
 N
P
C
s 
pe
r
zo
ne
 Clone 1
Clone 2400
CT
L
11
49
C>
A
11
85
+1
G>
A
34
31
-32
_d
up
GT
54
25
C>
T
66
19
C>
T
p<0.0001
n.s.
n.s.
n.s. n.s.
n.s.
n.s. n.s.
n.s.
n.s. n.s.
n.s. n.s.
n.s.
n.s. n.s.
p<
0.
00
01
p<
0.
00
01 p<0.0001 p<0.0001
p<0.0001
p=0.0003
p<0.0001
p<0.0001
(legend on next page)
542 Stem Cell Reports j Vol. 14 j 541–550 j April 14, 2020
Isogenic NF1-Mutant hiPSC-Derived NPCs and
Astroglia Have Increased RAS Activity and
Proliferation
To determine the consequence of the different NF1 gene
mutations on neurofibromin signal transduction and func-
tion in human CNS cells, NF1-mutant and control hiPSCs
were first differentiated into neural progenitor cells
(NPCs) capable of generating both neurons (TUJ1+ cells)
and glia (S100b+ cells) (Figure S2B). Because neurofibromin
primarily functions as an RAS-GAP to control cell prolifer-
ation, we initially assessed RAS activity. Consistent with
this negative RAS regulatory property, all NF1-mutant
NPCs exhibited a comparable 1.8- to 2.2-fold increase in
RAS-GTP relative to the isogenic control (Figure 1C).
Importantly, the addition of growth factors (fibroblast
growth factor [FGF] or brain-derived neurotrophic factor
[BDNF]) did not further increase RAS activity in the NF1-
mutant lines, but resulted in greater RAS-GTP levels in
the control lines, equivalent to the levels observed in the
unstimulated NF1-mutant lines (Figures 1D and 1E). These
findings demonstrate that a heterozygous NF1 mutation
phenocopies the effect of exogenous growth factor stim-
ulation on RAS activation. In addition, all NF1-mutant
NPCs exhibited increased cell division, as demonstrated
by increased bromodeoxyuridine (BrdU) incorporation
(2.6- to 3.2-fold increase; Figure 1F) and total cell number
(1.9- to 2-fold increase; Figure 1G). To evaluate the effects
of distinct NF1 gene mutations on the production of
NPCs in a 3D model of human brain development, we
generated cerebral organoids from the control and NF1-
mutant hiPSC lines. Despite repeated efforts, we were un-
able to derive organoids from two of the sevenNF1-mutant
hiPSC lines (c.2041C > T and c.6513T > A), but successfully
generated organoids from the control and five of the seven
NF1-mutant hiPSC lines (c.1149C > A, c.1185+1G > A,
c.3431-32_dupGT, c.5425C > T, c.6619C > T; Figure 1H).
The organoids formed radially organized ventricle-like
structures populated by SOX2+ NPCs by 16 days in vitro
(DIV). Similar to the 2D cultures, allNF1-mutant organoids
exhibited a 2.8- to 3.2-fold increase in RAS activity (Fig-
ure 1I), as well as a 1.6- to 2.2-fold increase in total NPCs
per ventricular zone at 16 DIV (Figure 1J).
Next, we sought to determine whether these heterozy-
gous NF1 mutational effects were observed in another
proliferating CNS cell type by differentiating the NPCs
into astrocytes (Figure 2A). Similar to the NPCs, NF1-
mutant astrocytes exhibited 2- to 2.3-fold increased RAS
activity (Figure 2B), 2.3- to 2.7-fold increased cell division
(Figure 2C), and 2.1- to 2.5-fold greater total cell number
(Figure 2D) relative to the control line. Consistent with
the 2D astrocytes, 56 DIV NF1-mutant organoids
had more EAAT1- and GFAP-expressing cells (astrocytes)
(Figure 2E) compared with control organoids. Importantly,
isogenic NF1-mutant NPCs and organoids were similar
to those of their respective patient-derived NPCs
(c.1185+1G > A; c.5425C > T; c.6513T > A) and organoids
(c.1185+1G > A; c.5425C > T) (Figures S3 and S4; Table S1)
in RAS activity and NPC proliferation, as well as to whole-
brain lysates from genetically engineered mice harboring
the analogous germline Nf1 gene mutations (c.1149C > A,
c.2041C>T, c.3431-32_dupGT, and c.5425C>T; Figure 3A).
Taken together, these data illustrate that all heterozygous
NF1 mutations increase RAS activity and RAS-regulated
cell proliferation in both human and murine CNS cells.
hiPSC-Derived NF1-Mutant Neurons Exhibit Both
Shared and Differential Deficits in 2D Cultures
As some children with NF1 exhibit cognitive deficits and
neurodevelopmental delays (Hyman et al., 2005, 2006;
Jett and Friedman, 2010; Morris and Gutmann, 2018),
we sought to determine the effects of distinctNF1 germline
mutations on human CNS neuronal function and differ-
entiation. Based on the observation that Nf1-mutant
(Nf1+/) mice exhibit increased GABAergic tone that
contributes to the observed deficits in learning and spatial
memory (Costa et al., 2002; Cui et al., 2008), we assayed
Figure 1. Isogenic NF1-Mutant hiPSC-Derived NPCs Exhibit Increased RAS Activity and Cell Proliferation
(A) Schematic diagram illustrating the position of the engineered NF1 patient mutations within the NF1 gene. The location of the RAS-GAP
domain is highlighted in black.
(B) Relative NF1 mRNA expression in isogenic NF1-mutant NPCs is similar to the controls.
(C–E) (C) Quantitation demonstrating increased RAS activity (RAS-GTP) in isogenic NF1-mutant NPCs relative to controls (CTL) before and
after the addition of (D) 10 mg/mL FGF or (E) BDNF. A minimum of three independent replicates was performed for each treatment
condition.
(F) BrdU incorporation is increased by 2.6- to 3.2-fold in NF1-mutant NPCs relative to control NPCs.
(G) 1.9- to 2-fold increases in total cell numbers were observed in NF1-mutant NPCs compared with controls.
(H) Representative bright-field images of embryoid bodies and cerebral organoids at 16 and 56 DIV.
(I and J) (I) Quantitation demonstrating increased RAS activity (2.8- to 3.2-fold) and (J) increased numbers of SOX2+ NPCs per ventricular
zone (1.6- to 2.2-fold) in 16 DIV NF1-mutant cerebral organoids relative to control organoids.
Each dot represents an independently generated data point derived from separate experiments and the two different clones for each line
are denoted as black versus gray dots. All data are represented as means ± SEM. (B, C, F, G, I, and J) One-way ANOVA with Tukey post-test.
(D and E) Two-way ANOVA with Bonferroni post-test. n.s., not significant. Scale bar, 1 mm.
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Figure 2. hiPSC-Derived NF1-Mutant Astroglia Exhibit Increased RAS Activity and Cell Proliferation
(A) NF1-mutant and control NPCs were differentiated into GFAP+, S100+, EAAT1+, and EAAT2+ astrocytes in 2D cultures. Scale bar, 100 mm.
(B) RAS-GTP was increased by 2- to 2.3-fold in NF1-mutant astrocytes relative to controls (CTL).
(C) Proliferation of NF1-mutant astrocytes was 2.3- to 2.7-fold higher relative to controls.
(D) Direct cell counting demonstrated a 2.1- to 2.5-fold increase in NF1-mutant astrocytes compared with controls.
(legend continued on next page)
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GABA levels in NPC-derived GABAergic neurons (Figures
3B and S3E). In all NF1-mutant neurons (2D cultures),
GABA levels were increased (6.5- to 7.8-fold) relative to
isogenic control neurons, revealing a shared abnormality
in all NF1-mutant GABAergic neurons.
In contrast, NF1-mutant NPCs in 2D cultures displayed
striking differences in dopamine (DA) (Figure 3C) levels.
DA levels were reduced by >70% in the c.1149C > A,
c.2041C > T, and c.6619C > T NF1 mutants, but by <40%
in the c.1185+1G > A, c.3431-32_dupGT, c.5425C > T,
and c.6513T > A NF1 mutants relative to the control line.
These differential effects mirror findings using patient-
derived NPCs (Figures S3E and S3F; Table S1) (Anastasaki
et al., 2015), as well as mice engineered with NF1 patient-
specific Nf1 germline mutations (Figure 3D) (Toonen
et al., 2016). Taken together, these findings demonstrate
the existence of differential effects of NF1 germline muta-
tions on neuronal differentiation in vitro.
Differential Effects of NF1Mutations on Cerebral
Organoid NPC Proliferation, Apoptosis and
Differentiation
To further explore the differential effects of NF1 muta-
tions in the developing human brain, we used the
more contextually relevant cerebral organoid platform.
Examination of NPC proliferation, apoptosis and
neuronal differentiation in 16 DIV cerebral organoids
revealed two distinct groups of NF1 mutants (Figure 4):
group 1 (c.1185+1G > A; c.5425C > T; c.6619C > T)
NF1 mutants exhibited increased NPC proliferation
(1.3- to 1.4-fold) and apoptosis (2- to 3-fold), but
had similar numbers of early (NeuroD1+, TUJ1+) and
late (MAP2+) immature neurons relative to controls.
In this manner, group 1 NF1 mutations increased
both proliferation and apoptosis during NPC differen-
tiation, allowing neurogenesis to proceed normally.
In contrast, group 2 (c.1149C > A; c.3431-32_dupGT)
NF1-mutant organoids had normal NPC proliferation,
but reduced NPC apoptosis (70%–92% reduction)
and very few immature neurons relative to the isogenic
controls (73%–84% reduction). In this latter group,
the reduction in NPC death was coupled with a
delay in neurogenesis, suggesting that inappropriate
survival of NPC subpopulations creates a barrier to
initiating timely neuronal differentiation. Importantly,
these observations persist in patient-derived cerebral
organoids harboring the same mutations (Figure S4;
Table S1).
(E) NF1-mutant cerebral organoids grown for 56 DIV had increased cells with GFAP+ fibers and increased numbers of EAAT1+ glial cells
compared with isogenic controls. Scale bars, 50 mm.
Each dot represents an independently generated data point derived from separate experiments and the two different clones for each line
are denoted as black versus gray dots. All data are represented as means ± SEM. One-way ANOVA with Tukey post-test.
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Figure 3. hiPSC-Derived NF1-Mutant Neu-
rons, NPCs, and Nf1-Mutant Mice Display
Molecular Similarities and Differences
(A) Nf1-mutant (1149C > A, 2041C > T, 3431-
32_dupGT, 5425C > T) genetically engineered
mouse brain lysates exhibit increased RAS ac-
tivity compared with wild-type littermate
controls.
(B) GABA levels are increased in all NF1-mutant
NPC-derived neurons relative to controls.
(C and D) Dopamine levels are differentially
reduced in (C) NF1-mutant NPCs relative to
controls and (D) Nf1-mutant genetically en-
gineered mouse brain lysates compared with
WT littermate controls.
Each dot represents an independently gener-
ated data point derived from separate experi-
ments and the two different clones for each
line are denoted as black versus gray dots. All
data are represented as means ± SEM. One-way
ANOVA with Tukey post-test.
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Conclusions
The findings described in this report, in combination with
compelling population-based genotype-phenotype associ-
ations, suggest that the germline NF1 gene mutation is
one of the factors that underlies clinical heterogeneity in
patients with NF1. Using an isogenic series of NF1-mutant
hiPSC lines, we identified differential NF1 mutational ef-
fects on human CNS cells and tissues. Importantly, unlike
previous studies, the use of an isogenic series of hiPSCs
eliminates other contributing factors, such as sex and
genomic variation (potential modifier genes), and permits
a direct examination of the effects of different NF1 gene
mutations. Moreover, this study raises several important
points relevant to NF1 pathobiology.
First, we established that all heterozygous NF1 gene
mutations similarly increase CNS NPC and astroglial cell
proliferation and RAS activity, which is consistent with
numerous reports demonstrating that neurofibromin
controls cell proliferation largely by regulating RAS activity
in mouse, swine, and Drosophila cells and tissues. More-
over, the regulation of RAS-mediated cell proliferation
by neurofibromin is further supported using paired
hiPSC-derived NPCs, heterozygous and homozygous for
the same NF1 gene mutation, where a clear gene dose de-
pendencywas revealed (C. Anastasaki, Personal Communi-
cation). Therefore, the vast majority of human clinical
trials for NF1-null tumors have appropriately used molecu-
larly targeted therapies that inhibit RAS and RAS down-
stream effectors (e.g., MEK) (Dombi et al., 2016).
Second, we demonstrated differential effects of NF1
germline mutations on neuronal differentiation. These dif-
ferential effects could reflect the fact that neurofibromin
functions as a high-affinity dimer, where different muta-
tions could change the overall architecture of the dimer
interface (Sherekar et al., 2020). Because neurons from
individuals with NF1 harbor only a single NF1 germline
mutation, different NF1 mutations likely cause unique
neuron-related pathologies. Therefore, the use of isogenic
hiPSCs revealed differential effects of distinct NF1 gene
mutations on NPC proliferation, apoptosis, and neuronal
differentiation not previously reported in the developing
Nf1-knockout (Nf1wt/neo) mouse brain. Given the high de-
gree of mutational specificity for autism symptomatology
in children with NF1 (Morris and Gutmann, 2018), these
findings suggest that investigations using Nf1 mice with
different patient germline Nf1 mutations might uncover
unique behavioral abnormalities not appreciated using
conventional Nf1 knockout mice (Costa et al., 2002; Om-
rani et al., 2015) and identify causative underlying molec-
ular mechanisms.
Third, the fact that the observed differences in neuronal
differentiation in cerebral organoids and NPC DA levels do
not correlate with RAS activation supports the existence of
non-RAS-mediated neurofibromin functions. In this re-
gard, neurofibromin also directly binds to several proteins
important for neuronal differentiation, spinogenesis, and
serotonin receptor activity, including collapsin response
mediator protein-2 (Patrakitkomjorn et al., 2008), synde-
can (Hsueh et al., 2001), and the 5-hydroxyltryptamine-6
receptor (Deraredj Nadim et al., 2016), through domains
distinct from the GRD. Moreover, the notion that non-
RAS-mediated neurofibromin functions exist in neurons
is reinforced by the presence of a neurofibromin isoform
containing an additional amino terminal exon (11alt12),
whose expression is restricted to postnatal brain neurons
(Gutmann et al., 1999). Future investigations aimed at
discovering novel neuron-specific neurofibromin binding
partners will be critical to understanding how NF1 muta-
tions differentially affect cognition and behavior in chil-
dren with NF1.
Finally, although population and murine studies pro-
vided the first evidence for NF1 genotype-phenotype cor-
relations, there had been no direct demonstration of the
primary effect of the NF1 mutation at the cellular and
tissue levels in humans. The use of this experimental hu-
man iPSC platform revealed NF1 mutational abnormal-
ities in human NPCs and neurons. Collectively, these
studies establish a foundational basis for future studies
aimed at unraveling mechanistic etiologies responsible
for NF1-specific CNS phenotypes, discovering new thera-
peutic targets, and assessing treatments relevant to preci-
sion medicine.
Figure 4. Differential Effects of NF1 Mutations on Cerebral Organoid Progenitor Cell Dynamics and Neurogenesis
(A and B) SOX2+ NPCs in the ventricular zones of group 1 NF1-mutant cerebral organoids exhibit (A) 1.3- to 1.4-fold increased proliferation
(Ki67+ cells; white arrowheads) and (B) 2- to 3-fold increased cell apoptosis (cleaved caspase-3; white arrowheads) compared with control
and group 2 cerebral organoids at 16 DIV.
(C–E) Decreased numbers of (C and D) early immature neurons (NeuroD1; TUJ1 white arrowheads) and (E) late immature neurons (MAP2;
white arrowheads) migrating into the periventricular zone of group 2 compared with group 1 and control cerebral organoids at 16 DIV.
(F) Quantifications of %Ki67+ NPCs, %cleaved caspase-3+ NPCs and NeuroD1+ immature neurons in NF1-mutant cerebral organoids
compared with controls at 16 DIV.
Each dot represents an independently generated data point derived from separate experiments and the two different clones for each line
are denoted as black versus gray dots. All data are represented as means ± SEM. One-way ANOVA with Dunnett post-test. n.s., not sig-
nificant. Scale bars, 10 mm (C) and 50 mm (A, B, D, and E).
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EXPERIMENTAL PROCEDURES
Human iPSCs
Seven distinctNF1-patient germlineNF1 genemutations (Transcript
ID NM_000267; c.1149C > A, c.1185+1G > A, c.2041C > T, c.3431-
32_dupGT, c.5425C > T, c.6513T > A, c.6619C > T)were individually
engineered using CRISPR/Cas9 technology into a single commer-
cially available male control human iPSC line (BJFF.6) by the Wash-
ington University Genome Engineering and iPSC Core (GEiC) facil-
ity. Heterozygous mutations were confirmed by NGS sequencing
(Bell et al., 2014), and two different clones were expanded for each
of the six NF1-mutant and the control lines (Figures S1A–S1C).
Only a single clone heterozygous for the c.6619C > TNF1mutation
could be generatedwithout any additional genomic insertions or de-
letions. Retention of heterozygosity in the hiPSCswas confirmed by
sequencing after five passages, as well as in all of the derivative cell
lines by RAS activity assays. Similar results were obtained after
each passage. In addition, iPSCs reprogrammed from the fibroblasts
of three NF1 patients (c.1185+1G > A; c.5425C > T; c.6513T > A) and
one control subject (Anastasaki et al., 2015) were used for subse-
quent analyses. For NPC differentiation, hiPSCs were passaged
onto PLO/Laminin (Millipore Sigma)-coated plates using ReLeSR
(STEMCELL Technologies), and seeded at 200,000 cells/cm2 in
NPC induction medium (50% DMEM F12 [Gibco], 50%Neurobasal
medium [Gibco], supplemented with N2, B27 [Fisher], 2 mMGluta-
MAX [Gibco], 10 ng/mL hLIF, 4 mM CHIR99021, 3 mM SB431541,
and 0.1 mMCompound E [all from STEMCELL Technologies]). Cells
were maintained in this medium supplemented with 2 mM dorso-
morphin for 3 days and without dorsomorphin (STEMCELL
Technologies) for an additional 5 days. NPCs were subsequently
incubated inNPCmaturationmedium (50%DMEM/F12, 50%Neu-
robasal medium supplemented with N2, B27, 2 mM GlutaMAX,
10 ng/mL hLIF, 3 mM CHIR99021 and 2 mM SB431541), and were
passaged weekly following Accutase (STEMCELL Technologies)
dissociation according to the manufacturer’s instructions. NPCs
were treated for 24 h with 10 mg/mL of FGF or BDNF (both
STEMCELL Technologies) to assess growth factor-induced cell
proliferation. GABAergic neurons were differentiated as described
previously (Liu et al., 2013). For astrocytic differentiation, NPCs
were plated on Primaria-coated plates in Astrocyte Growth Media
(ScienCell) for a minimum of 2 weeks and a maximum of ten
passages (Tcw et al., 2017). Cerebral organoids were generated as
described previously (Lancaster and Knoblich, 2014) with minor
modifications: embryoid bodies were cultured in NIM (STEMCELL
Technologies) supplemented with 20 mM Rock inhibitor Y27632
(Millipore) and 4 ng/mL basic FGF (Peprotech) for the first 5 days,
followed by NIM alone for an additional 4 days, before direct trans-
fer to cerebral organoid media without Matrigel embedding. Cere-
bral organoids were maintained for up to 56 DIV. All experiments
used at least three biological replicates from two independently
generated hiPSC clones.
RNA Extraction, cDNA Production, qPCR, and
Targeted Allele Expression Analysis
Total RNA was extracted from snap-frozen cell pellets of three
independent passages of two clones per hiPSC line, using
QIAGEN RNeasy Mini Kit. Total RNA was reverse-transcribed into
cDNA using an Applied Biosystems High-Capacity cDNA Reverse
Transcription Kit as per the manufacturer’s instructions. Real-
time quantitative PCR (qPCR) was performed using TaqMan
Gene Expression assays NF1 (Hs01035108_m1) and GAPDH
(Hs02786624_g1; internal control), and relative NF1 expression
was calculated using the DDCT analysis method following the
manufacturer’s instructions (Thermo Fisher Scientific). For allele-
specific expression analyses, primer pairs including Illumina
adapter sequences concatenated to their 50 ends were used for all
NF1-mutant hiPSCs to initially amplify the mutation-surrounding
region, and later to add the P5 sites, P7 sites, and sample-specific in-
dex (Supplemental Experimental Procedures). The samples were
pooled and the amplicons were deep-sequenced on a MiSeq ma-
chine. Illumina adapters, 5’ and 30 bases with quality scores <25,
as well as sequences <25 bases long were trimmed using Trimmo-
matic v.0.331 software. Trimmed reads were aligned to the human
reference genome hg19 using STARv2.52 software and allele reads
were calculated using Integrative Genomics Viewer v.2.3.293.
Immunohistochemistry and ELISA Assays
Immunocytochemistry on NPCs, astrocytes, and neurons was
performed following established protocols (Anastasaki et al.,
2015) using the antibodies described (Table S2). RAS activity
(Thermo Fisher Scientific), GABA, dopamine (both Rocky Moun-
tain Diagnostics) detection (Anastasaki et al., 2015), BrdU prolifer-
ation assays (Roche), and direct cell counting were performed as
described previously (Toonen et al., 2016). Immunohistochem-
istry on cryosections of cerebral organoids was performed as
described previously (Sloan et al., 2018). Aminimumof three inde-
pendent samples representing different passages of two separate
clones were used for each line.
Mice
All animals were maintained on an inbred C57BL/6 background us-
ing a 12-h light/dark cycle with ad libitum access to food and water.
Heterozygous Nf1 mice were generated to harbor point mutations
corresponding to the human c.1149C > A, c.2041C > T,
c.3431_32dupGT, and c.5425C > T mutations. The c.1149C > A,
c.2041C > T, and c.3431_32dupGT mice were generated using
C57BL/6 embryonic stem cells backcrossed a minimum of 10 times
to wild-type C57BL/6 mice, while the c.5425C > Tmice were gener-
ated byCRISPR/Cas9 engineering on aC57BL/6 genetic background
andheterozygousmutationwas confirmedby direct sequencing. All
micewere used in accordance with an approved Animal Studies Pro-
tocol at the Washington University School of Medicine.
Statistics
All statistical testswere performedusingGraphPad Prism 5 software.
We performed t tests, one- or two-way analysis of variance (ANOVA)
with Dunnett or Bonferroni post-test correction using GraphPad
Prism 5 software. Statistical significance was set at p < 0.05.
ACCESSION NUMBERS
The accession number for the deep sequencing data re-
ported in this paper is GEO: GSE144601.
548 Stem Cell Reports j Vol. 14 j 541–550 j April 14, 2020
SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/
10.1016/j.stemcr.2020.03.007.
AUTHOR CONTRIBUTIONS
C.A., M.L.W., and D.H.G. designed and analyzed the experiments.
C.A., M.L.W., K.H., J.B.P., N.D.K., J.C., O.C., and J.D.D. conducted
and/or interpreted the experiments. The article was assembled by
C.A., M.L.W., and D.H.G. D.H.G. was responsible for the final pro-
duction of the manuscript.
ACKNOWLEDGMENTS
This work was supported by an R50 Research Specialist Award from
theNational Cancer Institute, USA (1-R50-CA233164-01 to C.A.), a
Young Investigator’s Award grant from theChildren’s Tumor Foun-
dation, USA (2018-01-003 to M.L.W.), and a Research Program
Award grant from the National Insitute of Neurological Disorders
and Stroke, USA (1-R35-NS07211-01 to D.H.G.). The GEiC Center
at WUSM engineered the hiPSCs and is subsidized by National
Cancer Institute, USA Cancer Center Support grant (P30-
CA091842). Dr. Gutmann has a licensing agreement for the
GFAP-Cre mouse strain with the Tuberous Sclerosis Alliance.
Received: April 19, 2019
Revised: March 5, 2020
Accepted: March 6, 2020
Published: April 2, 2020
REFERENCES
Anastasaki, C., Morris, S.M., Gao, F., and Gutmann, D.H. (2017).
Children with 5’-end NF1 gene mutations are more likely to
have glioma. Neurol. Genet. 3, e192.
Anastasaki, C., Woo, A.S., Messiaen, L.M., and Gutmann, D.H.
(2015). Elucidating the impact of neurofibromatosis-1 germline
mutations on neurofibromin function and dopamine-based
learning. Hum. Mol. Genet. 24, 3518–3528.
Bell, C.C., Magor, G.W., Gillinder, K.R., and Perkins, A.C. (2014). A
high-throughput screening strategy for detecting CRISPR-Cas9
inducedmutations using next-generation sequencing. BMCGeno-
mics 15, 1002.
Bolcekova, A., Nemethova, M., Zatkova, A., Hlinkova, K., Poz-
gayova, S., Hlavata, A., Kadasi, L., Durovcikova, D., Gerinec, A.,
Husakova, K., et al. (2013). Clustering of mutations in the 5’ tertile
of the NF1 gene in Slovakia patients with optic pathway glioma.
Neoplasma 60, 655–665.
Costa, R.M., Federov, N.B., Kogan, J.H., Murphy, G.G., Stern, J.,
Ohno, M., Kucherlapati, R., Jacks, T., and Silva, A.J. (2002). Mech-
anism for the learning deficits in a mouse model of neurofibroma-
tosis type 1. Nature 415, 526–530.
Cui, Y., Costa, R.M.,Murphy,G.G., Elgersma, Y., Zhu, Y., Gutmann,
D.H., Parada, L.F., Mody, I., and Silva, A.J. (2008). Neurofibromin
regulation of ERK signaling modulates GABA release and learning.
Cell 135, 549–560.
Deraredj Nadim, W., Chaumont-Dubel, S., Madouri, F., Cobret, L.,
De Tauzia, M.L., Zajdel, P., Benedetti, H., Marin, P., and Morisset-
Lopez, S. (2016). Physical interaction between neurofibromin
and serotonin 5-HT6 receptor promotes receptor constitutive ac-
tivity. Proc. Natl. Acad. Sci. U S A 113, 12310–12315.
Dombi, E., Baldwin, A., Marcus, L.J., Fisher, M.J.,Weiss, B., Kim, A.,
Whitcomb, P., Martin, S., Aschbacher-Smith, L.E., Rizvi, T.A., et al.
(2016). Activity of selumetinib in neurofibromatosis type 1-related
plexiform neurofibromas. N. Engl. J. Med. 375, 2550–2560.
Fisher, M.J., Belzberg, A.J., de Blank, P., De Raedt, T., Elefteriou, F.,
Ferner, R.E., Giovannini,M., Harris, G.J., Kalamarides,M., Karajan-
nis, M.A., et al. (2018). 2016 Children’s Tumor Foundation confer-
ence on neurofibromatosis type 1, neurofibromatosis type 2, and
schwannomatosis. Am. J. Med. Genet. A 176, 1258–1269.
Gutmann, D.H., Zhang, Y., and Hirbe, A. (1999). Developmental
regulation of a neuron-specific neurofibromatosis 1 isoform.
Ann. Neurol. 46, 777–782.
Hsueh, Y.P., Roberts, A.M., Volta, M., Sheng, M., and Roberts, R.G.
(2001). Bipartite interaction between neurofibromatosis type I pro-
tein (neurofibromin) and syndecan transmembrane heparan sul-
fate proteoglycans. J. Neurosci. 21, 3764–3770.
Hyman, S.L., Shores, A., and North, K.N. (2005). The nature and
frequency of cognitive deficits in children with neurofibromatosis
type 1. Neurology 65, 1037–1044.
Hyman, S.L., Arthur Shores, E., and North, K.N. (2006). Learning
disabilities in children with neurofibromatosis type 1: subtypes,
cognitive profile, and attention-deficit-hyperactivity disorder.
Dev. Med. Child Neurol. 48, 973–977.
Jett, K., and Friedman, J.M. (2010). Clinical and genetic aspects of
neurofibromatosis 1. Genet. Med. 12, 1–11.
Kehrer-Sawatzki, H., Mautner, V.F., and Cooper, D.N. (2017).
Emerging genotype-phenotype relationships in patients with large
NF1 deletions. Hum. Genet. 136, 349–376.
Koczkowska, M., Callens, T., Gomes, A., Sharp, A., Chen, Y., Hicks,
A.D., Aylsworth, A.S., Azizi, A.A., Basel, D.G., Bellus, G., et al.
(2018). Expanding the clinical phenotype of individuals with a
3-bp in-frame deletion of the NF1 gene (c.2970_2972del): an up-
date of genotype-phenotype correlation. Genet.Med. 21, 867–876.
Korf, B.R. (2013). Neurofibromatosis. Handb. Clin. Neurol. 111,
333–340.
Lancaster, M.A., and Knoblich, J.A. (2014). Generation of cerebral
organoids from human pluripotent stem cells. Nat. Protoc. 9,
2329–2340.
Liu, Y., Liu, H., Sauvey, C., Yao, L., Zarnowska, E.D., and Zhang,
S.C. (2013). Directed differentiation of forebrain GABA interneu-
rons from human pluripotent stem cells. Nat. Protoc. 8, 1670–
1679.
Morris, S.M., and Gutmann, D.H. (2018). A genotype-phenotype
correlation for quantitative autistic trait burden in neurofibroma-
tosis 1. Neurology 90, 377–379.
Omrani, A., van der Vaart, T., Mientjes, E., van Woerden, G.M.,
Hojjati, M.R., Li, K.W., Gutmann, D.H., Levelt, C.N., Smit, A.B.,
Silva, A.J., et al. (2015). HCN channels are a novel therapeutic
target for cognitive dysfunction in neurofibromatosis type 1.
Mol. Psychiatry 20, 1311–1321.
Stem Cell Reports j Vol. 14 j 541–550 j April 14, 2020 549
Patrakitkomjorn, S., Kobayashi, D., Morikawa, T., Wilson, M.M.,
Tsubota, N., Irie, A., Ozawa, T., Aoki, M., Arimura, N., Kaibuchi,
K., et al. (2008). Neurofibromatosis type 1 (NF1) tumor suppressor,
neurofibromin, regulates the neuronal differentiation of PC12 cells
via its associating protein, CRMP-2. J. Biol. Chem. 283, 9399–9413.
Pinna, V., Lanari, V., Daniele, P., Consoli, F., Agolini, E., Margiotti,
K., Bottillo, I., Torrente, I., Bruselles, A., Fusilli, C., et al. (2015).
p.Arg1809Cys substitution in neurofibromin is associated with a
distinctive NF1 phenotype without neurofibromas. Eur. J. Hum.
Genet. 23, 1068–1071.
Rojnueangnit, K., Xie, J., Gomes, A., Sharp, A., Callens, T., Chen, Y.,
Liu, Y., Cochran,M., Abbott,M.A., Atkin, J., et al. (2015). High inci-
dence of Noonan syndrome features including short stature and
pulmonic stenosis in patients carrying NF1 missense mutations
affecting p.Arg1809: genotype-phenotype correlation. Hum. Mu-
tat. 36, 1052–1063.
Sharif, S., Upadhyaya, M., Ferner, R., Majounie, E., Shenton, A.,
Baser, M., Thakker, N., and Evans, D.G. (2011). A molecular anal-
ysis of individuals with neurofibromatosis type 1 (NF1) and optic
pathway gliomas (OPGs), and an assessment of genotype-pheno-
type correlations. J. Med. Genet. 48, 256–260.
Sherekar, M., Han, S.W., Ghirlando, R., Messing, S., Drew, M., Ra-
bara, D., Waybright, T., Juneja, P., O’Neill, H., Stanley, C.B., et al.
(2020). Biochemical and structural analyses reveal that the tumor
suppressor neurofibromin (NF1) forms a high-affinity dimer. J.
Biol. Chem. 295, 1105–1119.
Sloan, S.A., Andersen, J., Pasca, A.M., Birey, F., and Pasca, S.P.
(2018). Generation and assembly of human brain region-specific
three-dimensional cultures. Nat. Protoc. 13, 2062–2085.
Tcw, J.,Wang,M., Pimenova, A.A., Bowles, K.R., Hartley, B.J., Lacin,
E., Machlovi, S.I., Abdelaal, R., Karch, C.M., Phatnani, H., et al.
(2017). An efficient platform for astrocyte differentiation from hu-
man induced pluripotent stem cells. StemCell Reports 9, 600–614.
Toonen, J.A., Anastasaki, C., Smithson, L.J., Gianino, S.M., Li, K.,
Kesterson, R.A., and Gutmann, D.H. (2016). NF1 germline muta-
tion differentially dictates optic glioma formation and growth in
neurofibromatosis-1. Hum. Mol. Genet. 25, 1703–1713.
Trevisson, E.,Morbidoni, V., Forzan,M., Daolio, C., Fumini, V., Par-
rozzani, R., Cassina, M., Midena, E., Salviati, L., and Clementi, M.
(2019). The Arg1038Gly missense variant in the NF1 gene causes a
mild phenotype without neurofibromas. Mol. Genet. Genomic
Med. 7, e616.
Upadhyaya, M., Huson, S.M., Davies, M., Thomas, N., Chuzha-
nova, N., Giovannini, S., Evans, D.G., Howard, E., Kerr, B., Grif-
fiths, S., et al. (2007). An absence of cutaneous neurofibromas asso-
ciated with a 3-bp inframe deletion in exon 17 of the NF1 gene
(c.2970-2972 delAAT): evidence of a clinically significant NF1 ge-
notype-phenotype correlation. Am. J. Hum. Genet. 80, 140–151.
550 Stem Cell Reports j Vol. 14 j 541–550 j April 14, 2020
Stem Cell Reports, Volume 14
Supplemental Information
Human iPSC-DerivedNeurons andCerebral Organoids EstablishDiffer-
ential Effects of Germline NF1 Gene Mutations
Corina Anastasaki, Michelle L. Wegscheid, Kelly Hartigan, Jason B. Papke, Nathan D.
Kopp, Jiayang Chen, Olivia Cobb, Joseph D. Dougherty, and David H. Gutmann
Supplementary Figures 
 
Figure S1. Isogenic NF1-mutant hiPSC sequencing and allele expression analysis of 
isogenic and patient-derived NF1-mutant hiPSCs. 
Figure S2. Analysis of isogenic hiPSCs, NPCs, and cerebral organoids. 
Figure S3. Comparisons between isogenic and patient-derived NF1-mutant hiPSC-
NPCs. 
Figure S4. Comparisons between isogenic and patient-derived NF1-mutant hiPSC-
organoids. 
 
Table S1. Inter-clone analysis of control and NF1-mutant hiPSC-derived cells and 
organoids. 
Table S2. Primary antibodies used.  
 
Supplementary Methods  
Figure S1. Isogenic NF1-mutant hiPSC sequencing and allele expression analysis 
of isogenic and patient-derived NF1-mutant hiPSCs. 
 
Figure S1. Sequencing of NF1-mutant hiPSCs. (A) Snapgene view of NGS sequencing of all 
NF1-mutant hiPSC clones. (Block only: control; Block/mod: introduced NF1 gene mutation). (B-
C) Table and histogram summarizing the percentage of sequence reads detected for the mutant 
and reference (wild-type) alleles at the mutation site at the genomic level. (D) Analysis of 
reference and mutant (SNP) allele expression in each NF1-mutant hiPSC line at the RNA level 
demonstrates that the wild-type reference allele is over-represented in all NF1-mutant hiPSCs 
relative to the mutation-bearing (SNP) allele. Data are represented as the percentages of 
reference and mutant reads relative to the total reads.  
Figure S2. Analysis of isogenic hiPSCs, NPCs, and cerebral organoids.  
 
Figure S2. (A) Immunofluorescence analysis of all hiPSCs with the NANOG, SOX2, OCT4A, 
SSEA-4, TRA-1-60, and TRA-1-81 pluripotency markers. Scale bar, 100µm. (B) NPCs were 
immunopositive for the SOX2, BLBP and Nestin neural stem cell markers (top two panels), and 
were multipotent, as illustrated by TUJ1+ and S100β+ double labeling (bottom panel).  Scale bars, 
100µm. (C) Control and NF1-mutant NPC-differentiated GABAergic neuronal cultures were 
immunopositive for GAD67 (green) and immunonegative for the excitatory neuron marker 
glutamate synthetase (GS; red). Scale bar, 100µm. 
 
  
Figure S3. Comparisons between isogenic and patient-derived NF1-mutant hiPSC-
NPCs.  
 
Figure S3. (A) Relative NF1 mRNA expression, (B) RAS activity, (C) BrdU incorporation, and (D) 
cell numbers are similar between the isogenic and their respective patient-derived NPC lines that 
harbor the same NF1 gene mutation. The top panels illustrate all the clones (Isogenic clones: I1, 
I2; white, grey circles, respectively; Patient-derived clones: P1, P2; orange and blue circles, 
respectively) employed for each assay, and represent comparisons between all NF1-mutant 
NPCs and controls. The bottom panels illustrate the individual comparisons between the isogenic 
(I1, I2) and their respective patient-derived (P1, P2) NPCs (CTL; 1185+1G>A; 5425C>T; 
6513T>A). Relative (E) GABA levels and (F) DA levels are similar between the isogenic and their 
respective patient-derived NPC lines harboring the same NF1 gene mutation. The top panels 
illustrate all the clones (Isogenic clones: I1, I2; white, grey circles, respectively; Patient-derived 
clones: P1, P2; orange and blue circles, respectively) employed for each assay, and represent 
the comparisons between all NF1-mutant NPCs and controls. The bottom panels illustrate the 
individual comparisons between the isogenic (I1, I2) and their respective patient-derived (P1, P2) 
NPCs (CTL; 1185+1G>A; 5425C>T; 6513T>A). All data are represented as means ± SEM; One-
way ANOVA with Tukey post-test. ns, not significant. (G) PCA plot and (H) histogram analysis 
illustrate differential clustering of gene expression between patient-derived and isogenic NPCs 
harboring two separate NF1 mutations (1185+1G>A; 6513T>A) or no NF1 mutation (control; 
CTL), following next-generation sequencing. 
 
  
Figure S4. Comparisons between isogenic and patient-derived NF1-mutant hiPSC-
organoids.  
 
  
Figure S4. Representative images of (A) NPC proliferation (Ki67+ cells; white arrowheads), (B) 
NPC apoptosis (cleaved caspase-3; white arrowheads), (C, D) early immature neurons (NeuroD1; 
TUJ1; white arrowheads), (E) late immature neurons (MAP2; white arrowheads) at 16DIV, and 
the production of (F) EAAT1+ glial cells and (G) GFAP+ fibers at 56DIV in cerebral organoids 
generated from 1185+1G>A and 5425C>T patient-derived hiPSC lines. Scale bars: (C) 10µm, (A, 
B, D, E, F, G) 50µm. There were no differences in (H) RAS activity or (I) SOX2+ NPCs per 
ventricular zone (VZ) between the isogenic NF1-mutant cerebral organoids and their 
corresponding patient-derived at 16DIV. There were no differences in (J) %Ki67+ NPCs per VZ, 
(K) %cleaved caspase-3+ NPCs per VZ, or (L) NeuroD1+ immature neurons between the isogenic 
NF1-mutant and their corresponding patient-derived cerebral organoids at 16DIV. The top panels 
illustrate all the clones (Isogenic clones: I1, I2; white, grey circles, respectively; Patient-derived 
clones: P1, P2; orange and blue circles, respectively) employed for each assay, and represent 
the comparisons between all NF1-mutant organoids and controls. The bottom panels illustrate the 
individual comparisons between the isogenic (I1, I2) and their respective patient-derived (P1, P2) 
NPCs (1185+1G>A; 5425C>T). All data are represented as means ± SEM; One-way ANOVA with 
Tukey post-test. ns, not significant.  
 
  
 Table S1. Inter-clone analysis of control and NF1-mutant hiPSC-derived cells and 
organoids. 
 
 
Table S1. Table detailing the inter-clone analyses of isogenic iPSC-derived NPCs and organoids, 
as well as isogenic versus patient-derived hiPSC-derived NPCs and organoids harboring the 
same germline NF1 mutations. There are no statistically significant differences in the  relative NF1 
mRNA expression in NPCs, RAS activity, BrdU incorporation, or cell number in NPCs or 
astrocytes, GABA and dopamine (DA) levels in NPCs, %Ki67+ progenitor cells per ventricular 
zone (VZ), RAS activity, NPCs per ventricular zone (VZ), NeuroD1+ cells or %cleaved caspase-
3+ progenitor cells per VZ in cerebral organoids. *t-test; P-values reported, **One-Way ANOVA; 
F / P-values reported, respectively. n/a: not applicable. 
  
Table S2. Primary antibodies used. 
Antibody Vendor Catalog No Host Application (dilution) 
BLBP Millipore ABN14 Rabbit ICC (1:200) 
Cleaved caspase-3 Cell Signaling 9664 Rabbit IF (1:250) 
EAAT1 Abcam ab416 Rabbit ICC, IF (1:500) 
EAAT2 Abcam ab41621 Rabbit ICC (1:500) 
GFAP Abcam ab4648 Mouse ICC, IF (1:500) 
Ki67 Fisher Scientific BDB556003 Mouse IF (1:100) 
MAP2 Abcam ab11267 Mouse IF (1:500) 
Nanog (D73G4) Cell Signaling 9656S Rabbit ICC (1:200) 
Nestin Abcam ab92391 Rabbit ICC (1:250) 
NeuroD1 Abcam ab60704 Mouse IF (1:500) 
Oct-4A (C30A3) Cell Signaling 9656S Rabbit ICC (1:200) 
S100β Abcam ab41548 Rabbit ICC (1:200) 
SOX2 Cell Signaling 4900S Mouse ICC (1:1000); IF (1:250) 
Sox2 (D6D9) Cell Signaling 9656S Rabbit ICC (1:200) 
SOX2 Abcam ab92494 Rabbit IF (1:250) 
SSEA4 (MC813) Cell Signaling 9656S Mouse ICC (1:200) 
TRA-1-60(S) Cell Signaling 9656S Mouse ICC (1:200) 
TRA-1-81 Cell Signaling 9656S Mouse ICC (1:200) 
TUJ-1 Abcam ab78078 Mouse ICC (1:1000) 
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Next Generation RNA Sequencing and Analysis. RNA was extracted from three independently-
generated samples of isogenic CTL or NF1-mutant (1185+1G>A; 6513T>A) NPCs, and one 
sample each from the non-isogenic CTL and patient-derived NF1-mutant NPCs harboring the 
same NF1 mutations. Samples were prepared according to library kit manufacturer’s protocol, 
indexed, pooled, and sequenced on an Illumina HiSeq. Basecalls and demultiplexing were 
performed with Illumina’s bcl2fastq software and a custom python demultiplexing program with a 
maximum of one mismatch in the indexing read. RNA-seq reads were then aligned to the 
Ensembl release 76 primary assembly with STAR version 2.5.1a. Gene counts were derived 
from the number of uniquely aligned unambiguous reads by Subread:featureCount version 
1.4.6-p5. Isoform expressions of known Ensembl transcripts were estimated with Salmon 
version 0.8.2.  Sequencing performance was assessed for the total number of aligned reads, 
total number of uniquely aligned reads, and features detected. The ribosomal fraction, known 
junction saturation, and read distribution over known gene models were quantified with RSeQC 
version 2.6.2. The raw gene count matrix was then imported into Partek Flow software, version 
8.0. Normalization size factors were calculated for all gene counts by CPM to adjust for 
differences in sequencing depth. Ribosomal genes and genes not expressed in the smallest 
group size minus samples greater than one count-per-million were excluded from further 
analysis. Gene-specific analysis was then performed using the lognormal with shrinkage model 
(limma-trend method) to analyze for differential expression between the three groups of 
samples. Principle component analysis (PCA) was conducted in Partek Flow using normalized 
gene counts. The "grouping" is simply a post hoc highlighting of the genotypes for assistance in 
visualizing that the different samples clustered together by genotype during the principle 
component. For further visualization, a heatmap was generated using the differential genes for 
each group filtered at p-values ≤ 0.05 and log fold-changes more extreme or equal to ±2. 
Features and samples were clustered using Pearson Correlation as a distance metric. Deep 
sequencing data has been submitted to GEO with accession number GSE144601.  
 
Allele-Specific Analysis Primers Used. The primers used for the first PCR reaction including the 
Illumina adaptor sequences were the following: 
1149C>A FW: GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTCTACTTGTTCAGTCCATGGTGG 
1149C>A REV: ACACTCTTTCCCTACACGACGCTCTTCCGATCTCCAATGCGGAATTGGTGATGA 
2041C>T FW: GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTAATTACTACGTACTCCTGGAGC 
2041C>T REV: ACACTCTTTCCCTACACGACGCTCTTCCGATCTGCAAGAGGTTATGCACTGAC 
3431-32_dupGT FW: GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTGACTGCAGTGAAGTTGA 
AGATG 
3431-32_dupGT REV: ACACTCTTTCCCTACACGACGCTCTTCCGATCTGTAGCTCTTGTCTGGAGAT 
CC 
5425C>T FW: GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTGAAGCCATTGTCCAGTCTATC 
5425C>T REV: ACACTCTTTCCCTACACGACGCTCTTCCGATCTGGTACAAGTTAAGGCACACAG 
6513T>A FW: GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTGACTCAGTCTGACAGAGTTCTC 
6513T>A REV: ACACTCTTTCCCTACACGACGCTCTTCCGATCTCTAGTTCTGTCCACTGGTCC 
6619C>T FW: GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTTGCCTTCCGTTCCAGTTACC 
6619C>T REV: ACACTCTTTCCCTACACGACGCTCTTCCGATCTGAGCTCTTGGTTGCAGGGAT 
The primers used for the second amplification PCR reaction which include the unique indexes 
employed to identify different sequencing products were the following: 
Primer 1.0 FW: AATGATACGGCGACCACCGAGATCTACACACACTCTTTCCCTACACGACGCTCTTC 
CGATCT 
Primer 1.0 SIC2 FW: AATGATACGGCGACCACCGAGATCTACACAATGAAACACTCTTTCCCTACA 
CGACGCTCTTCCGATCT 
Common REV: GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT 
Index 1 REV: CAAGCAGAAGACGGCATACGAGATAAATAGATGGTGACTGGAGTTC 
Index 2 REV: CAAGCAGAAGACGGCATACGAGATCAGAGGAGAGTGACTGGAGTTC 
Index 3 REV: CAAGCAGAAGACGGCATACGAGATCGTATAGATGTGACTGGAGTTC 
Index 4 REV: CAAGCAGAAGACGGCATACGAGATAAGGGCTCAGTGACTGGAGTTC 
 
